IDYA

ANALYST NOTE: IDEAYA BIOSCIENCES, INC. (IDYA) DATE: 2026-06-13 CURRENT PRICE: $31.23

1. Structural Readiness

State: Forming Aggressive/Pre-Breakout Entry: Current price ($31.23) represents a holding zone above the structural support line. Breakout Level: Pending confirmation above the current consolidation range. Current Price: $31.23 Extension: Not applicable (price is within the consolidation range, not extended above the breakout level). ATR Context: Current ATR is 4.8% (High). This indicates elevated volatility, consistent with a biotech name in a "Forming" state where binary clinical data or regulatory milestones are anticipated.

2. Thesis Layer

Primary Secular Thesis: Biotech & GLP-1 → Oncology (Tier Direct, High Confidence). Company Role: IDEAYA is a direct beneficiary of the secular shift toward precision oncology and synthetic lethality, specifically targeting genetically defined cancers (GNAQ/GNA11 mutations) in Uveal Melanoma (UM) and other solid tumors. Thesis Weighting: The company is a pure-play exposure to the "Oncology" theme. While the "GLP-1" tag in the membership list is present, IDEAYA's direct exposure is strictly to the "Oncology" sub-sector via its PKC inhibitor portfolio. The "GLP-1" association in the metadata appears to be a broad sector classification rather than a direct product exposure for IDEAYA. The conviction is driven by the high unmet medical need in Uveal Melanoma and the potential for a first-in-class therapy to address a "cold" tumor microenvironment.

3. Business Analysis

Business Model: IDEAYA Biosciences is a precision medicine oncology company focused on the discovery, development, and commercialization of transformative therapies based on synthetic lethality. The company leverages a partnership-heavy model to fund development and share risk. Industry: Healthcare / Biotechnology / Oncology. Key Operations & Evidence (as of 2026-06-13):

• Flagship Asset (Darovasertib): An oral, potent, and selective PKC inhibitor (E18). It is the company's most advanced clinical program.
• Strategic Partnerships:
• Pfizer: In 2026, IDEAYA maintains a partnership where Pfizer supplies binimetinib (MEK inhibitor) and crizotinib (cMET inhibitor) for combination trials in tumors with GNAQ/GNA11 mutations (E12, E24).
• GSK: A collaboration agreement exists where GSK is responsible for 80% of costs if they exercise an option, with a potential $50 million option exercise fee (E3, E4).
• Servier: Entered into a license agreement in August 2025, generating $6.6 million in collaboration revenue for the quarter ended March 31, 2026 (E11).
• Clinical Pipeline Status:
• OptimUM-02: Full enrollment of 437 patients was completed in December 2025. Management expects to report Overall Survival (OS) data to support a full approval filing (E16).
• OptimUM-10: A randomized Phase 3 trial in the neoadjuvant setting initiated in 2025, enrolling ~450 patients (E19).
• OptimUM-11: A global Phase 3 combination trial (darovasertib + crizotinib) in the adjuvant setting is planned for initiation in the first half of 2026 (E21).
• Breakthrough Therapy Designation: In March 2025, the FDA granted BTD for darovasertib in the neoadjuvant treatment of primary uveal melanoma (E9).
• Financial Position: Management stated in February 2026 that current cash and marketable securities are sufficient to fund operations for at least 12 months from the issuance date (E14). The company received a $210 million upfront payment in a major deal (likely the Pfizer or similar strategic alliance referenced in E17) and is eligible for up to $320 million in milestones (E17).

4. Archetype and Conviction

Archetype: Growth Leader. Rationale: The company fits the "Growth Leader" archetype due to its advanced clinical stage (Phase 3), significant strategic partnerships providing capital and resources, and the potential for a transformative therapy in a high-unmet-need indication. The financial spine shows negative EPS (-4.39 FY1, -3.79 FY2), which is standard for pre-commercial biotech growth leaders burning cash to reach commercialization. Valuation & Conviction Stack:

• Thesis Strength: High. The focus on synthetic lethality in GNAQ/GNA11-mutated tumors addresses a specific, difficult-to-treat patient population.
• Evidence Quality: Strong. Multiple primary filings (E9, E15, E16, E17, E19) confirm active Phase 3 trials and regulatory designations.
• Rerating Potential: Significant. A successful OS readout from OptimUM-02 or the initiation of OptimUM-11 could trigger a re-rating from a "clinical-stage" to a "near-commercial" valuation.
• Conviction: The setup is a "Forming" coil, meaning the structural quality is present but the breakout (confirmation of the thesis via price action) has not yet occurred. The conviction is high on the *business* fundamentals, but the *setup* is incomplete.

5. Invalidation, Strengthening, and Gaps

What Would Invalidate:

• Negative or delayed data readouts from the OptimUM-02 trial (OS data) or failure to initiate OptimUM-11 as planned.
• A breach of the 12-month cash runway (E14) requiring dilutive financing before a catalyst.

What Would Strengthen:

• A confirmed breakout above the current consolidation range (confirming the "Forming" coil).
• Positive top-line data from OptimUM-02 (PFS or OS) reported in Q1 2026 (E15).
• Successful initiation of the OptimUM-11 Phase 3 combination trial in H1 2026 (E21).
• Exercise of the GSK option or additional milestone payments.

Gaps in Evidence:

• Commercialization Timeline: While Phase 3 is active, the exact timeline for NDA submission and potential approval is not detailed in the provided evidence, only the data submission plans.
• Competitive Landscape: No specific evidence regarding competing therapies in the Uveal Melanoma space is provided in the EVIDENCE block.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key evidence: FDA Breakthrough Therapy designation for darovasertib in neoadjuvant UM (E9); Full enrollment of OptimUM-02 with OS data expected (E16); $210M upfront payment and $320M milestone potential secured (E17); Cash runway sufficient for 12 months (E14). Key risks: Binary clinical trial failure in OptimUM-02 or OptimUM-11; Potential cash burn exceeding runway if trials are delayed; Lack of commercial revenue prior to approval; High volatility (4.8% ATR) leading to stop-outs. Sizing hint: Position size should reflect the binary nature of the upcoming data readouts and the "Forming" setup status; avoid full allocation until breakout confirmation. Expected path: Management expects to report OptimUM-02 OS data in Q1 2026 and initiate OptimUM-11 in H1 2026; successful data could lead to a breakout from the current consolidation range. Expected horizon: 3 to 6 months for the next major catalyst (OptimUM-02 data readout).